Navigation Links
Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
Date:3/11/2009

Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/ImClone Systems*/Merck KGaA's Erbitux will drive the colorectal cancer market to grow by $900 million to $7.8 billion in 2017.

The new Pharmacor report entitled Colorectal Cancer finds that market growth will be driven by the launches of Avastin and Erbitux into the adjuvant setting in 2011 in the United States and 2012 in Europe. Additionally, among the emerging therapies that will launch for colorectal cancer over the next several years, AstraZeneca's Recentin, Pfizer's Sutent and Sanofi-Aventis/Regeneron's VEGF Trap will account for 9.2 percent of market sales in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although monoclonal antibodies such as Avastin and Erbitux and emerging tyrosine kinase inhibitors and vascular endothelial growth factor inhibitors will drive growth, generic erosion will take market share away from some currently-available therapies, including oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine and Yakult Honsha's Elplat). The expected entrance of generic oxaliplatin in the U.S. colorectal cancer market in late 2009 and in Japan in 2013 will reduce major-market sales of branded forms of this agent by almost $800 million in 2017.

The report also finds that there is significant remaining unmet need in the market for treating patients with mutated KRAS genes who do not respond to therapy using epidermal growth factor receptor (EGFR) inhibitors.

"In recent years, clinical data have shown that patients with mutated KRAS genes do not respond to treatment with EGFR inhibitors, creating a significant unmet need for efficacious agents in the second-line setting for patients who have progressed on Avastin," said Decision Resources Analyst Marcus Hoyle. "This unmet need, coupled with a rising incidence of colorectal cancer, presents a considerable commercial opportunity for drug developers in this market."

*ImClone Systems is a wholly-owned subsidiary of Eli Lilly and Company.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                Decision Resources, Inc.
    Christopher Comfort               Elizabeth Marshall
    781-296-2597                      781-296-2563
    ccomfort@dresources.com           emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
2. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
3. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
4. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
5. Avastin Added to Chemo Helps Women With Advanced Cancer
6. Off-Label Avastin Use for Wet Macular Degeneration
7. FDA OKs Avastin for Advanced Breast Cancer
8. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
9. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
10. Many More Patients Can Now Benefit from Avastins Proven Survival Benefits
11. Taxol with avastin produces noteworthy results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey ... , The 550 employees of Sun Health Senior Living (SHSL) may not ... reduces their doctor and prescription copays for the year, while holding the line on ...
(Date:5/26/2016)... ... 2016 , ... Eating Recovery Center, Washington (ERC ... brand new child and adolescent residential treatment center on June 1. The 18-bed, ... specialized eating disorder treatment and access to life-saving care. , To celebrate, ERC ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian Mehling, ... The conference was held during May 5-6, 2016 in Chicago, IL, USA. Dr. ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Een app die artsen over de ... kunnen behandelen, hun kennis kunnen delen en van elkaar ... en revolutionaire MDLinking App, ontwikkeld door een internationale groep ... Flu en oncologisch chirurg dr. Gijs van Acker ... op dinsdag 24 mei officieel gepresenteerd op het Amsterdam ...
(Date:5/23/2016)... -- Global Paclitaxel Market 2016 Industry Research ... and the Paclitaxel analysis in this study is supported ... its players. This is the latest Paclitaxel ... current state of the industry while providing a basic ... industry chain structure. The Paclitaxel market analysis is provided ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology: